Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Patients Receiving Chemoradiation Therapy for Head and Neck Cancer

Inclusion Criteria: * Subject must have a body weight less than 150 kg at screening * Have recently-diagnosed, pathologically-confirmed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx that will be treated with chemoradiation therapy as first line treatment(postoperative patients are eligible, if surgery is \< 6 weeks prior to initiation of radiotherapy. * Plan to receive a continuous course of conventional external beam irradiation * Plan to receive a standard cisplatin chemotherapy regimen Exclusion Criteria: * Pregnant or breastfeeding * Have head and neck tumors of the lips, sinuses, salivary glands or unknown primary tumor * Prior radiation to the head and neck * Have a plan to receive cetuximab (Erbitux) in conjunction with chemotherapy * Had curative surgery more than 6 weeks prior to the initiation of radiotherapy * Have current oral mucositis * Presence of active infectious disease excluding oral candidiasis * Chronic immunosuppression * Seropositive for HIV or hepatitis B surface antigen or C antibody * Used an investigational agent within 30 days of randomization * Have a known sensitivity to any investigational agent